Literature DB >> 9593005

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.

Y Maeda1, D J Venzon, H Mitsuya.   

Abstract

Investigations were done to determine whether the replication kinetics of human immunodeficiency virus (HIV)-1 were altered when the virus acquired a set or subsets of five mutations (A62V, V75I, F77L, F116Y, and Q151M) in the pol gene conferring resistance to multiple dideoxynucleosides. In the absence of drugs, the replication rate of all infectious clones generated was comparable to that of wild type HIV-1. However, in the presence of zidovudine or didanosine, the comparative order for replication was HIV-1(62/75/77/116/151) > HIV-1(77/116/151) > HIV-1(75/77/116/151) approximately HIV-1(151), whereas that for drug resistance was HIV-1(75/77/116/151) > HIV-1(62/75/77/116/151) > or = HIV-1(77/116/151) > HIV-1(151). The virologic features of these infectious mutants suggest that HIV-1 develops drug resistance through one or more mutations, which, however, sacrifice replicative capability; then it finally acquires optimal replication competence by additional mutations when the multi-dideoxynucleoside-resistant mutant emerges.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593005     DOI: 10.1086/515282

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.

Authors:  E I Kodama; S Kohgo; K Kitano; H Machida; H Gatanaga; S Shigeta; M Matsuoka; H Ohrui; H Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Estimating relative fitness in viral competition experiments.

Authors:  A F Marée; W Keulen; C A Boucher; R J De Boer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

4.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

5.  The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.

Authors:  Mian-er Cong; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

6.  Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.

Authors:  Daisuke Nameki; Eiichi Kodama; Mieko Ikeuchi; Naoto Mabuchi; Akira Otaka; Hirokazu Tamamura; Mutsuhito Ohno; Nobutaka Fujii; Masao Matsuoka
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Molecular epidemiology of HIV type 1 in newly diagnosed patients in southern Spain.

Authors:  Michael J McConnell; Fernando Docobo-Pérez; Rosario C Mata; Felipe Fernandez-Cuenca; Pompeyo Viciana; Luis F López-Cortés; Mónica Trastoy; Jerónimo Pachón; Pilar Pérez-Romero
Journal:  AIDS Res Hum Retroviruses       Date:  2008-06       Impact factor: 2.205

8.  Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Robert A Smith; Donovan J Anderson; Bradley D Preston
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

9.  Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation.

Authors:  Miguel E Quiñones-Mateu; Mahlet Tadele; Mariona Parera; Antonio Mas; Jan Weber; Héctor R Rangel; Bikram Chakraborty; Bonaventura Clotet; Esteban Domingo; Luis Menéndez-Arias; Miguel A Martínez
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.

Authors:  Kazuki Izumi; Eiichi Kodama; Kazuya Shimura; Yasuko Sakagami; Kentaro Watanabe; Saori Ito; Tsuyoshi Watabe; Yukihiro Terakawa; Hiroki Nishikawa; Stefan G Sarafianos; Kazuo Kitaura; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.